Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Abbott Laboratories (NY: ABT )

130.01 -0.60 (-0.46%)
Streaming Delayed Price Updated: 11:58 AM EST, Feb 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
42 43 Next >
How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula
New research suggests Depakote ingredient could have a new clinical function. This could present more profit potential for drugmakers as well as investors. 
Via MarketBeat
7 Hot Healthcare Stocks With the Potential to Outperform
These healthcare stocks to buy now have the potential to outperform the market over the long-term because their businesses are strong. 
Via InvestorPlace
Which Healthcare Stock Is a Better Pick in 2023?
With a potential recession on the horizon, healthcare stocks could be good picks for investors. Which of these three is best? 
Via InvestorPlace
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: NUVASIVE (Nasdaq – NUVA), Oak Street Health (NYSE – OSH), Argo Group International Holdings, Ltd. (NYSE - ARGO), Cardiovascular Systems, Inc. (Nasdaq – CSII)
From Brodsky & Smith LLC
Via GlobeNewswire
Why Cardiovascular Systems Stock Is Soaring Today
The medtech company has agreed to a buyout offer from Abbott Laboratories. 
Via The Motley Fool
Is This Dividend King a Buy for Income Investors?
This healthcare company has one of the most established payouts in its sector. 
Via The Motley Fool
Better Buy: Johnson & Johnson or AbbVie?
The healthcare giants are favored by income-oriented investors but have a potentially disruptive year ahead. 
Via The Motley Fool
Candy? Flowers? These Top Stocks Offer You Something Even Sweeter
These stocks may reward you over time. 
Via The Motley Fool
The 7 Most Undervalued Dividend Aristocrats to Buy
With so many uncertainties ahead, investors may take comfort in the stability of the most undervalued dividend aristocrats to buy. 
Via InvestorPlace
Abbott-Cardiovascular Systems Acquisition Could Further Add Uncertainty Over Surmodics' Product: Analyst Downgrades Stock
Via Benzinga
Cardiovascular Systems (NASDAQ: CSII) Enters Into Agreement to be Acquired By Abbott Labs (NYSE: ABT) For $890 Million
Cardiovascular Systems, Inc. (NASDAQ: CSII) is engaged as a medical device company, which is focused on the research, development and 
Via Spotlight Growth
What 5 Analyst Ratings Have To Say About Abbott Laboratories
Via Benzinga
Here's How Much You Would Have Made Owning Abbott Laboratories Stock In The Last 10 Years
Via Benzinga
Why Is Cardiovascular Systems (CSII) Stock Up 48% Today?
Cardiovascular Systems (CSII) stock is rising higher on Thursday following news that Abbott (ABT) intends to acquire the company. 
Via InvestorPlace
Abbott Adds Complementary Technologies To Its Vascular Offering Via Cardiovascular Systems Deal For $890M
Via Benzinga
3 Dividend Stocks That Will Hold Up No Matter the Market Conditions
These stocks could boost your portfolio in bear markets and bull markets. 
Via The Motley Fool
Baby Formula Blues Hit Abbott Laboratories Stock Hard in 2022. Can It Rebound in 2023?
The healthcare stock fell 22% last year. 
Via The Motley Fool
2 Beaten-Down Stocks With Stable Dividends to Buy In 2023
You can bet the farm on these companies' dividends. 
Via The Motley Fool
3 Unstoppable Dividend Stocks to Buy in February
All three belong to the elite group of stocks known as Dividend Kings. 
Via The Motley Fool
2 Top Dividend Growth Stocks to Buy in February
They don't offer the highest yields, but these strongly profitable businesses are poised to raise their payouts at a blistering pace. 
Via The Motley Fool
5 Top Stocks to Buy Now
This eclectic mix of stocks will help diversify your portfolio. 
Via The Motley Fool
Sector Shift Stalls Healthcare Stocks But Biotech Shows Gains In January
Biotech stocks are off to a great start in 2023 with the IBB up 4.5% and the XBI up 7.7%. 
Via Talk Markets
GE Healthcare Technology: Speculating On Dividends
GE Healthcare released a solid report and gave steady guidance that includes ample room in the cash flow for a dividend, should the board choose to pay one. 
Via MarketBeat
Is Abbott Laboratories a Good Dividend Stock to Buy Now?
At least four Wall Street banks recently raised their price targets for the healthcare giant. 
Via The Motley Fool
Stock Market Rally Powers Higher Amid Big Earnings From Tesla, Boeing, Microsoft, American Express: Weekly Review
Stocks reacted well to uneven earnings and economic reports. 
Via Investor's Business Daily
NIKE To Rally Over 23%? Here Are 10 Other Analyst Forecasts For Thursday
Keybanc raised the price target for D.R. Horton, Inc. (NYSE: DHI) from $97 to $109. Keybanc analyst Kenneth Zener maintained an Overweight rating. D.R. Horton shares fell 1.6% to close at $95.48 on... 
Via Benzinga
Abbott's Sales and Earnings Are Sinking: Should Investors Worry?
There's more to the story than the negative trends for Abbott's top and bottom lines. 
Via The Motley Fool
Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?
Johnson & Johnson and Abbott Laboratories are 2 dividend kings guiding for growth in 2023 and are on track to increase their yield yet again. 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Why Abbott Laboratories Stock Got Whacked on Wednesday
Double beats for its latest quarter couldn't keep the bears away from the company's shares on Hump Day. 
Via The Motley Fool
Abbott Laboratories (ABT) Q4 2022 Earnings Call Transcript
ABT earnings call for the period ending December 31, 2022. 
Via The Motley Fool
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
42 43 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.